Lorlatinib INN

Composition: Each film coated tablet contains Lorlatinib INN 100mg.

Indications: It is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic Non-small Cell Lung Cancer (NSCLC) whose disease has progressed on
• Crizotinib and at least one other ALK inhibitor for metastatic disease; or
• Alectinib as the first ALK inhibitor therapy for metastatic disease; or
• Ceritinib as the first ALK inhibitor therapy for metastatic disease

Dosage and administration: The recommended dosage of Lorlatinib is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. It should be taken at the same time each day. If a dose is missed, then the missed dose should be taken unless the next dose is due within 4 hours. 2 doses should not be taken at the same time to make up for a missed dose. Or, as directed by the registered physicians.

Use in pregnancy and lactation: It can cause fetal harm when administered to a pregnant woman. Pregnant women should be advised of the potential risk to a fetus. Women should be advised not to breastfeed during treatment with Lorlatinib and for 7 days after the final dose.

Packing: Each container contains 30 capsules in a box.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2023 Designed and Developed by ATI Limited.